AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25811755 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep duration (night + midday)
Number of subjects: 1970
Study 25812009 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide × 1
Number of subjects: 668
Study 25812009 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metformin × 2 days
Number of subjects: 668
Study 25812438 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (5 mCi)
Number of subjects: 20
Study 25812438 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (10 mCi)
Number of subjects: 20
Study 25812438 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (15 mCi)
Number of subjects: 20
Study 25812924 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal visual implant (Alpha IMS)
Number of subjects: 29
Study 25813372 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare Ventricular Assist Device (HVAD)
Number of subjects: 332
Study 25815033 — intervention group
Group type: EXPERIMENTAL
Intervention: WATSU (WaterShiatsu)
Number of subjects: 9
Study 25815033 — intervention group
Group type: COMPARATOR
Intervention: Passive control (no treatment)
Number of subjects: 9
Study 25815190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand in Hand intervention (4-8 couple sessions with a psychologist in addition to usual care)
Number of subjects: 199
Study 25815190 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 199
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal islet cell transplantation with 2-5 × 10(6) β-cells per kilogram of body weight
Number of subjects: 56
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable plasma GAD65
Number of subjects: 56
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate levels of plasma GAD65
Number of subjects: 56
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic nude rat recipients without hyperglycemic correction
Number of subjects: 56
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured human β-cells after acute insult
Number of subjects: 56
Study 25816051 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GAD65 detection
Number of subjects: 56
Study 25818272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised ventilator settings (SVS) at 24 hours
Number of subjects: 478
Study 25818272 — intervention group
Group type: COMPARATOR
Intervention: Baseline PaO₂/FiO₂
Number of subjects: 478
Study 25818272 — intervention group
Group type: COMPARATOR
Intervention: Usual care at 24 hours without SVS
Number of subjects: 478
Study 25818754 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 contrast agents used in Coronary CT angiography
Number of subjects: 0
Study 25818754 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 25819287 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Rate Brachytherapy (HDR-BT)
Number of subjects: 0
Study 25819643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg once every 4 weeks for six doses, then every 12 weeks until disease progression, unacceptable toxic effects, or refusal to continue treatment.
Number of subjects: 29
Study 25819852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto®)
Number of subjects: 0
Study 25819852 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care anticoagulant treatment
Number of subjects: 0
Study 25820067 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccines (3 vaccinations)
Number of subjects: 1218
Study 25820067 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccines (increased DNA dosage)
Number of subjects: 1218
Study 25820067 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1218
Study 25820067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 1218
Study 25820067 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccines
Number of subjects: 1218
Study 25820680 — intervention group
Group type: EXPERIMENTAL
Intervention: CardShock risk Score including variables such as ACS aetiology, age, previous myocardial infarction, prior coronary artery bypass, confusion, low LVEF, and blood lactate levels.
Number of subjects: 219
Study 25820680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ACS aetiology.
Number of subjects: 219
Study 25820680 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality rate.
Number of subjects: 219
Study 25821795 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF173*C genotype carriers
Number of subjects: 256
Study 25821795 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD patients
Number of subjects: 256
Study 25821795 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unstable angina pectoris (UAP)
Number of subjects: 256
Study 25821795 — intervention group
Group type: COMPARATOR
Intervention: C genotype
Number of subjects: 256
Study 25821795 — intervention group
Group type: COMPARATOR
Intervention: 173*CC genotype
Number of subjects: 256
Study 25821963 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + 3TC + LPV/r
Number of subjects: 80
Study 25822102 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline ARMC5 genetic alterations identified in 20 unrelated and 2 related individuals (39.3% prevalence).
Number of subjects: 56
Study 25822102 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMC5 sequence changes predicted to be damaging by in silico analysis.
Number of subjects: 56
Study 25822102 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected patients carrying a variant predicted to be damaging were all African Americans.
Number of subjects: 56
Study 25822102 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for ARMC5 sequence variants in cohorts of primary aldosteronism and metabolic syndrome, particularly in African Americans.
Number of subjects: 56
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment with 'safe' mrLRP
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment with 'unsafe' mrLRP
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment MRI reassessment with 'safe' ymrLRP
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment MRI reassessment with 'unsafe' ymrLRP
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (EMVI)
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (tumors < 4.0 cm from anal verge)
Number of subjects: 279
Study 25822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (anterior tumors)
Number of subjects: 279
Study 25822727 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicirc instrument with topical lidocaine/prilocaine anesthetic
Number of subjects: 110
Study 25822820 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (agalα; 0.2 mg/kg every other week)
Number of subjects: 100
Study 25823600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 0
Study 25823600 — intervention group
Group type: COMPARATOR
Intervention: No Oral Immunotherapy (No OIT)
Number of subjects: 0
Study 25823737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating T cells selected for HPV E6 and E7 reactivity (HPV-TILs) infused after lymphocyte-depleting chemotherapy and followed by aldesleukin administration.
Number of subjects: 9
Study 25823737 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-TILs infusion product
Number of subjects: 9
Study 25823737 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of HPV-reactive T cells in peripheral blood 1 month after treatment
Number of subjects: 9
Study 25823919 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone buccal film (BBN)
Number of subjects: 249
Study 25824111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment regimens (VDD: bortezomib, liposomal doxorubicin, dexamethasone; RVD: lenalidomide, bortezomib, dexamethasone)
Number of subjects: 0
Study 25824111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment regimens
Number of subjects: 0
Study 25824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg twice daily for 14 days
Number of subjects: 44
Study 25824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg once daily for 14 days
Number of subjects: 44
Study 25824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg once daily with a high-fat breakfast
Number of subjects: 44
Study 25824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine divided dosing (e.g., 1,500 mg/day)
Number of subjects: 44
Study 25824215 — intervention group
Group type: COMPARATOR
Intervention: Rifapentine with a low-fat breakfast
Number of subjects: 44
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) without lytic agent
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDT and catheter-directed thrombolysis (CDT)
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: RT in combination with CDT
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment approaches
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic PCDT treatment
Number of subjects: 329
Study 25824314 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet procedure
Number of subjects: 329
Study 25824400 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic complex remedy (Pascallerg®)
Number of subjects: 123
Study 25824474 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2022
Study 25824474 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2022
Study 25824692 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen with cyclophosphamide (CY), total body irradiation (TBI), antithymocyte globulin (ATG), and fludarabine (FLU)
Number of subjects: 130
Study 25824692 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen with TBI 300 cGy, CY, FLU, and ATG
Number of subjects: 130
Study 25824692 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen
Number of subjects: 130
Study 25825008 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus-containing lesions (TCLs) present
Number of subjects: 4449
Study 25825008 — intervention group
Group type: COMPARATOR
Intervention: No thrombus-containing lesions (TCLs)
Number of subjects: 4449
Study 25825044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker
Number of subjects: 253
Study 25825044 — intervention group
Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM)
Number of subjects: 253
Study 25825044 — intervention group
Group type: COMPARATOR
Intervention: Tilt testing (TT)
Number of subjects: 253
Study 25825044 — intervention group
Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 253
Study 25825044 — intervention group
Group type: COMPARATOR
Intervention: Non-diagnostic tests with ILR
Number of subjects: 253
Study 25825476 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (20 mg/d) and trastuzumab (6 mg/kg/3 weeks) for 6 weeks, followed by paclitaxel (80 mg/m2/1 week), trastuzumab, and afatinib for 12 weeks, followed by epirubicin (90 mg/m2/3 weeks), cyclophosphamide (600 mg/m2/3 weeks), and trastuzumab for 12 weeks
Number of subjects: 65
Study 25825476 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib and trastuzumab
Number of subjects: 65
Study 25825625 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) administered stroke symptom questionnaire (QVSFS)
Number of subjects: 322
Study 25825625 — intervention group
Group type: COMPARATOR
Intervention: Assessment by two trained neurologists
Number of subjects: 322
Study 25825629 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic ICAD positive individuals
Number of subjects: 200
Study 25825629 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic ICAD negative individuals
Number of subjects: 200
Study 25826274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided sampling
Number of subjects: 47
Study 25827180 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH-PD frames
Number of subjects: 20
Study 25827180 — intervention group
Group type: COMPARATOR
Intervention: SSFP-PD images
Number of subjects: 20
Study 25827220 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 minute post gadolinium T1 time
Number of subjects: 1208
Study 25827220 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 time
Number of subjects: 1208
Study 25827220 — intervention group
Group type: EXPERIMENTAL
Intervention: Partition coefficient
Number of subjects: 1208
Study 25827220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 AHA/ASCVD risk score
Number of subjects: 1208
Study 25827757 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (AHI: 5-15/h and >30 % of TST with IFL)
Number of subjects: 754
Study 25827757 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 30 % of TST with IFL
Number of subjects: 754
Study 25827820 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (60 mg every other day)
Number of subjects: 70
Study 25827941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous) for 12 months
Number of subjects: 334
Study 25828318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scores
Number of subjects: 0
Study 25828395 — intervention group
Group type: EXPERIMENTAL
Intervention: Age/Sex/Gene Expression Score (ASGES) testing
Number of subjects: 320
Study 25828395 — intervention group
Group type: COMPARATOR
Intervention: Low ASGES (ASGES ≤15)
Number of subjects: 320
Study 25828395 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ASGES (ASGES >15)
Number of subjects: 320
Study 25828395 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up major adverse cardiac event/revascularization rate
Number of subjects: 320
Study 25829395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg kg(-1)
Number of subjects: 67
Study 25829395 — intervention group
Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 67
Study 25829400 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1,000 mg/day
Number of subjects: 2265
Study 25829804 — intervention group
Group type: EXPERIMENTAL
Intervention: Abcertin® administered at the same dose as imiglucerase (30 to 55 U/kg every other week) for 24 weeks
Number of subjects: 5
Study 25829804 — intervention group
Group type: EXPERIMENTAL
Intervention: Abcertin® continued for another 24 weeks in three patients
Number of subjects: 5
Study 25830171 — intervention group
Group type: COMPARATOR
Intervention: Emergency Department patients
Number of subjects: 0
Study 25830321 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 15841
Study 25830321 — intervention group
Group type: COMPARATOR
Intervention: Standard screening
Number of subjects: 15841
Study 25830416 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable cluster sizes
Number of subjects: 0
Study 25831265 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT eHealth tool
Number of subjects: 200
Study 25832001 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN-α) treatment
Number of subjects: 275
Study 25832001 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 275
Study 25832466 — intervention group
Group type: EXPERIMENTAL
Intervention: BMTP-11
Number of subjects: 0
Study 25833388 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anesthetic handovers using a detailed checklist of 55 items.
Number of subjects: 441
Study 25833390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with ifosfamide and vinorelbine (IVB)
Number of subjects: 26
Study 25833390 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 26
Study 25833826 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and selenium supplementation at physiological concentrations
Number of subjects: 0
Study 25833826 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of zinc and selenium
Number of subjects: 0
Study 25833826 — intervention group
Group type: COMPARATOR
Intervention: Control patients without sepsis
Number of subjects: 0
Study 25833826 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sepsis
Number of subjects: 0
Study 25833956 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 25833968 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiation (eating a meal to satiation)
Number of subjects: 16
Study 25833968 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (not eating for 4 hours)
Number of subjects: 16
Study 25833973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-Free Mass Index (FFMI) in quartiles 3 and 4
Number of subjects: 3181
Study 25833973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-Free Mass Index (FFMI) in quartile 4 (>19.5 kg/m²)
Number of subjects: 3181
Study 25833973 — intervention group
Group type: COMPARATOR
Intervention: Body composition (FMI and FFMI)
Number of subjects: 3181
Study 25833973 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 3181
Study 25833975 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dairy intake
Number of subjects: 10010
Study 25833975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy products
Number of subjects: 10010
Study 25834212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week for up to 12 weeks or 20 weeks
Number of subjects: 268
Study 25834952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma DNA testing
Number of subjects: 1700000
Study 25834952 — intervention group
Group type: COMPARATOR
Intervention: Serum-based screening
Number of subjects: 1700000
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg daily
Number of subjects: 12
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg daily
Number of subjects: 12
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily
Number of subjects: 12
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 intravenously (days 1, 8, and 15)
Number of subjects: 12
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) as prophylactic anticoagulant
Number of subjects: 12
Study 25837499 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment-related adverse events (AEs)
Number of subjects: 12
Study 25837513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Number of subjects: 0
Study 25837801 — intervention group
Group type: EXPERIMENTAL
Intervention: Early levosimendan administration (perioperatively up to the first hour after ICU admission)
Number of subjects: 159
Study 25837801 — intervention group
Group type: COMPARATOR
Intervention: Late levosimendan administration (later than the first hour after ICU admission)
Number of subjects: 159
Study 25838266 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N7 IIV after priming with H7N7 LAIV
Number of subjects: 0
Study 25838266 — intervention group
Group type: COMPARATOR
Intervention: H7N7 IIV
Number of subjects: 0
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nasal splints
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sinusitis
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing age
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of absorbable nasal packing
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status (multidimensional QOL)
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to resolution of nasal crusting
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to resolution of mucopurulence
Number of subjects: 100
Study 25839931 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to resolution of synechia
Number of subjects: 100
Study 25840034 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI 1h-algorithm
Number of subjects: 1811
Study 25840428 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS who developed GDM
Number of subjects: 72
Study 25840428 — intervention group
Group type: COMPARATOR
Intervention: Women with PCOS who did not develop GDM
Number of subjects: 72
Study 25840600 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 0
Study 25840600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25840640 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography
Number of subjects: 135
Study 25840640 — intervention group
Group type: EXPERIMENTAL
Intervention: RV fractional area change
Number of subjects: 135
Study 25840640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferolateral strain
Number of subjects: 135
Study 25840640 — intervention group
Group type: COMPARATOR
Intervention: Conventional echocardiographic parameters
Number of subjects: 135
Study 25840829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy (ISTDP), average of 7.3 sessions
Number of subjects: 1082
Study 25840829 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients referred but never treated)
Number of subjects: 1082
Study 25840894 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging with dual-focus (NBI-DF)
Number of subjects: 270
Study 25840894 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging techniques (white light)
Number of subjects: 270